摘要
目的调查艾滋病病毒(HIV)感染男男性行为者抑郁状态的发生情况及其相关因素。方法纳入HIV感染男男性行为者316例,进行流调中心抑郁量表(CES-D)的横断面测试。采用多因素Logistic回归模型分析抑郁状态相关因素。结果67例受试者(21.2%)处于抑郁状态(CES-D≥16)。多因素Logsitic回归分析显示,感染6个月内开始抗病毒治疗[比值比(OR)=0.44,95%可信区间(CI):0.22~0.89]和既往抑郁症病史(OR=8.46,95%CI:2.69~26.59)是抑郁状态的独立相关因素,而抗病毒治疗方案、治疗持续时间、CD4^+T淋巴细胞计数、病毒抑制情况与抑郁状态无显著相关性(均P>0.05)。结论感染6个月内开始抗病毒治疗和既往抑郁症病史是HIV感染男男性行为者抑郁状态的独立、显著相关因素,早期开始抗病毒治疗可能对HIV感染者精神状况具有保护性作用。
Objective To investigate the prevalence and related factors of depressive status in HIV-infected men who have sex with men(MSM).Methods In this cross-sectional study,316 HIV-infected MSM were enrolled,and all participants completed the Center for Epidemiological Studies Depression(CES-D).Multiple logistic regression model was used to evaluate the related factors of depressive status.Results 67(21.2%)participants were defined as having depressive status(CES-D≥16).Multiple logistic regression analysis suggested that initiation of anti-retroviral therapy(ART)within 6 months of HIV infection(OR=0.44,95%CI:0.22-0.89)and past major depressive disorder(OR=8.46,95%CI:2.69-26.59)were independently related to depressive status in HIV-infected MSM(P<0.05);while ART duration,ART regimen,CD4^+T cells,and undetectable HIV RNA were not associated factors(all P>0.05).Conclusion Initiation of ART within 6 months of HIV infection and past major depressive disorder are independent and significant factors of depressive status in HIV-infected MSM.Early ART initiation may be protective for the mental state in HIV infection.
作者
康婧
耿文清
姜拥军
丁海波
KANG Jing;GENG Wen-qing;JIANG Yongjun;DING Haibo(NHC Key Laboratory of AIDS Immunology(China Medical University),Department of Laboratory Medicine,the First Affiliated Hospital of China Medical University,Shenyang 110001,China;Key Laboratory of AIDS Immunology of Liaoning Province,the First Affiliated Hospital of China Medical University,Shenyang 110001;Key Laboratory of AIDS Immunology,Chinese Academy of Medical Sciences,Shenyang 110001)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2019年第12期1234-1237,共4页
Chinese Journal of Aids & STD
基金
国家“十三五”科技重大专项(2017ZX10201101)。
